Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial, (Nature Medicine, (2023), 10.1038/s41591-023-02704-x)

Karim Fizazi; Arun A. Azad; Nobuaki Matsubara; Joan Carles; Andre P. Fay; Ugo De Giorgi; Jae Young Joung; Peter C.C. Fong; Eric Voog; Robert J. Jones; Neal D. Shore; Curtis Dunshee; Stefanie Zschäbitz; Jan Oldenburg; Dingwei Ye; Xun Lin; Cynthia G. Healy; Nicola Di Santo; A. Douglas Laird; Fabian Zohren; Neeraj Agarwal

doi:10.1038/s41591-024-02835-9

Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial, (Nature Medicine, (2023), 10.1038/s41591-023-02704-x)

Karim Fizazi, Arun A. Azad, Nobuaki Matsubara, Joan Carles, Andre P. Fay, Ugo De Giorgi, Jae Young Joung, Peter C.C. Fong, Eric Voog, Robert J. Jones, Neal D. Shore, Curtis Dunshee, Stefanie Zschäbitz, Jan Oldenburg, Dingwei Ye, Xun Lin, Cynthia G. Healy, Nicola Di Santo, A. Douglas Laird, Fabian ZohrenNeeraj Agarwal

Résultats de recherche: Contribution à un journal › !!Comment/debate

1 Citation (Scopus)

Résumé

Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-023-02704-x, published online 4 December 2023. In the version of the article initially published, the top right label in Fig. 4e, now reading “Median PSF2”, was a duplicate of the top right label in Fig. 4d. The error has been corrected in the HTML and PDF versions of the article.

langue originale	Anglais
Pages (de - à)	1505
Nombre de pages	1
journal	Nature Medicine
Volume	30
Numéro de publication	5
Les DOIs	https://doi.org/10.1038/s41591-024-02835-9
état	Publié - 1 mai 2024

Accès au document

10.1038/s41591-024-02835-9

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Fizazi, K., Azad, A. A., Matsubara, N., Carles, J., Fay, A. P., De Giorgi, U., Joung, J. Y., Fong, P. C. C., Voog, E., Jones, R. J., Shore, N. D., Dunshee, C., Zschäbitz, S., Oldenburg, J., Ye, D., Lin, X., Healy, C. G., Di Santo, N., Laird, A. D., ... Agarwal, N. (2024). Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial, (Nature Medicine, (2023), 10.1038/s41591-023-02704-x). Nature Medicine, 30(5), 1505. https://doi.org/10.1038/s41591-024-02835-9

@article{39ef4099d87b4978b573bf2be4689c12,

title = "Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial, (Nature Medicine, (2023), 10.1038/s41591-023-02704-x)",

abstract = "Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-023-02704-x, published online 4 December 2023. In the version of the article initially published, the top right label in Fig. 4e, now reading “Median PSF2”, was a duplicate of the top right label in Fig. 4d. The error has been corrected in the HTML and PDF versions of the article.",

author = "Karim Fizazi and Azad, {Arun A.} and Nobuaki Matsubara and Joan Carles and Fay, {Andre P.} and {De Giorgi}, Ugo and Joung, {Jae Young} and Fong, {Peter C.C.} and Eric Voog and Jones, {Robert J.} and Shore, {Neal D.} and Curtis Dunshee and Stefanie Zsch{\"a}bitz and Jan Oldenburg and Dingwei Ye and Xun Lin and Healy, {Cynthia G.} and {Di Santo}, Nicola and Laird, {A. Douglas} and Fabian Zohren and Neeraj Agarwal",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = may,

day = "1",

doi = "10.1038/s41591-024-02835-9",

language = "English",

volume = "30",

pages = "1505",

journal = "Nature Medicine",

issn = "1078-8956",

number = "5",

}

Fizazi, K, Azad, AA, Matsubara, N, Carles, J, Fay, AP, De Giorgi, U, Joung, JY, Fong, PCC, Voog, E, Jones, RJ, Shore, ND, Dunshee, C, Zschäbitz, S, Oldenburg, J, Ye, D, Lin, X, Healy, CG, Di Santo, N, Laird, AD, Zohren, F & Agarwal, N 2024, 'Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial, (Nature Medicine, (2023), 10.1038/s41591-023-02704-x)', Nature Medicine, VOL. 30, Numéro 5, p. 1505. https://doi.org/10.1038/s41591-024-02835-9

Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial, (Nature Medicine, (2023), 10.1038/s41591-023-02704-x). / Fizazi, Karim; Azad, Arun A.; Matsubara, Nobuaki et al.
Dans: Nature Medicine, Vol 30, Numéro 5, 01.05.2024, p. 1505.

Résultats de recherche: Contribution à un journal › !!Comment/debate

TY - JOUR

T1 - Publisher Correction

T2 - First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial, (Nature Medicine, (2023), 10.1038/s41591-023-02704-x)

AU - Fizazi, Karim

AU - Azad, Arun A.

AU - Matsubara, Nobuaki

AU - Carles, Joan

AU - Fay, Andre P.

AU - De Giorgi, Ugo

AU - Joung, Jae Young

AU - Fong, Peter C.C.

AU - Voog, Eric

AU - Jones, Robert J.

AU - Shore, Neal D.

AU - Dunshee, Curtis

AU - Zschäbitz, Stefanie

AU - Oldenburg, Jan

AU - Ye, Dingwei

AU - Lin, Xun

AU - Healy, Cynthia G.

AU - Di Santo, Nicola

AU - Laird, A. Douglas

AU - Zohren, Fabian

AU - Agarwal, Neeraj

PY - 2024/5/1

Y1 - 2024/5/1

N2 - Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-023-02704-x, published online 4 December 2023. In the version of the article initially published, the top right label in Fig. 4e, now reading “Median PSF2”, was a duplicate of the top right label in Fig. 4d. The error has been corrected in the HTML and PDF versions of the article.

AB - Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-023-02704-x, published online 4 December 2023. In the version of the article initially published, the top right label in Fig. 4e, now reading “Median PSF2”, was a duplicate of the top right label in Fig. 4d. The error has been corrected in the HTML and PDF versions of the article.

UR - http://www.scopus.com/inward/record.url?scp=85183756719&partnerID=8YFLogxK

U2 - 10.1038/s41591-024-02835-9

DO - 10.1038/s41591-024-02835-9

M3 - Comment/debate

AN - SCOPUS:85183756719

SN - 1078-8956

VL - 30

SP - 1505

JO - Nature Medicine

JF - Nature Medicine

IS - 5

ER -